Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IT-141 in Recurrent or Refractory Solid Tumors
NCT03096340Phase 1Terminated
- Sponsor
- Intezyne Technologies
- Start
- Mar 2017
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of IT-141 in solid tumor, sponsored by Intezyne Technologies. Primary endpoint: Maximum Tolerated Dose at 18 months. Started Mar 2017; status: terminated.
02
Drugs
IT-141
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03096340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096340.